Screener
Rigel Pharmaceuticals RIGL Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Intangible assets, net | 24,160 | 24,748 |
| Deferred income tax asset | 243,279 | 245,852 |
| Operating lease right-of-use assets | 785 | 920 |
| Other assets | 2,357 | 1,908 |
| Total assets | $504,608 | $513,594 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,486 | $7,191 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's other non-current assets?
- Rigel Pharmaceuticals (RIGL) reported other non-current assets of $2.36M in Q1 2026.
- How has Rigel Pharmaceuticals's other non-current assets changed year-over-year?
- Rigel Pharmaceuticals's other non-current assets increased by 55.5% year-over-year, from $1.52M to $2.36M.
- What is the long-term trend for Rigel Pharmaceuticals's other non-current assets?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's other non-current assets has grown at a 18.3% compound annual growth rate (CAGR), from $824K to $1.91M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Rigel Pharmaceuticals's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude